Inventiva (NASDAQ:IVA) Shares Up 6.8% – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price shot up 6.8% during mid-day trading on Tuesday . The stock traded as high as $4.10 and last traded at $4.1640. 1,025,597 shares changed hands during mid-day trading, an increase of 75% from the average daily volume of 587,467 shares. The stock had previously closed at $3.90.

Wall Street Analyst Weigh In

IVA has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Truist Financial initiated coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inventiva presently has an average rating of “Buy” and an average target price of $16.56.

Inventiva Price Performance

The company has a 50-day moving average of $4.47 and a 200 day moving average of $5.32.

Institutional Investors Weigh In On Inventiva

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP purchased a new position in shares of Inventiva during the 4th quarter worth about $18,600,000. ADAR1 Capital Management LLC purchased a new position in shares of Inventiva during the fourth quarter valued at approximately $12,601,000. Millennium Management LLC grew its stake in shares of Inventiva by 2,267.7% during the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after buying an additional 2,540,540 shares during the last quarter. UBS Group AG raised its holdings in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after buying an additional 2,634,580 shares during the period. Finally, SymBiosis Capital Partners LLC purchased a new stake in shares of Inventiva in the fourth quarter worth approximately $12,090,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.